A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Part of paid clinical trials in Bradenton, Florida.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07465653
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • HJB647 low dose — DRUG
    Study drug low dose in capsule form
  • HJB647 high dose — DRUG
    Study drug high dose in capsule form
  • Placebo — OTHER
    Placebo control in capsule form

Study Details

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

Key Dates

Start date
Mar 18, 2026
Status verified
Apr 2026
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Taken by mouth as capsules
  • Experimental: HJB647 low dose
    Taken by mouth as capsule
  • Experimental: HJB647 high dose
    Taken by mouth as capsule

Primary Outcome Measure

Number of participants with Adverse Events (AEs) [ Time Frame: Up to 33 days ]

Central Contacts

  • Novartis Pharmaceuticals
    1-888-669-6682
  • Novartis Pharmaceuticals
    +41613241111

Locations (3)

FacilityCityStateZIPSite coordinators
Synergy HealthcareBradentonFlorida34208
Shannon Stickels
Patrick Weston (PRINCIPAL_INVESTIGATOR)
Nature Coast Clinical Research LLCInvernessFlorida34452
Jill Barnett
+1 352 341 2100
Rafik Abadier (PRINCIPAL_INVESTIGATOR)
Jacksonville Center for ClinicalJacksonvilleFlorida32216
Sara Villotti
+1 904 730 0101
Michael J Koren (PRINCIPAL_INVESTIGATOR)

Find similar trials in Bradenton, FL

By condition

Related Studies